Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: BlueRockDiamonds #BRD set for a strong 2018 Watch here

EXCLUSIVE: Energy security underlines value in InfraStrata NI gas storage project
EXCLUSIVE: BlueRockDiamonds #BRD set for a strong 2018


Member Info for inanaco


Premium Member

Send a private message to inanaco

Member Since: Wed, 19th Oct 2011

Number of Share Chat Posts (all time): 26,681
Number of Share Chat Posts (last 30 days): 185

Last Posted: Thu 18:44


Post Distribution over the last 30 days




Thu 18:44

That will give you an indicative indicator because SCIB1 outperforms Onconsecs products

OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting

SAN DIEGO, April 26, 2018 -- OncoSec Medical Incorporated (�OncoSec� or the �Company� (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, will present a trial-in-progress poster presentation from its global, multi-center, registration-directed open-label Phase 2b clinical trial, PISCES/KEYNOTE-695, assessing the OncoSec's investigational therapy, ImmunoPulse� IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid or "tavo"] with electroporation), and the approved anti-PD-1 therapy pembrolizumab, in patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy. The poster presentation will occur at the upcoming American Society of Clinical Oncology (ASCO) 2018 Annual Meeting to be held on June 1-5, 2018, in Chicago, IL.
Wed 11:18

failed
Wed 11:18

Failed ...
Wed 11:13

Failed ... LOL
Mon 12:13

Goes of on one .... re-post this ...

Agema Historical Posts

""The market took advantage of a 31% discount. What idiot would not. A no brainier.""

Discounts to sp�s are nearly always took up. It�s always virtually an instant profit. What fund would turn that down.!

Agema's Folly Circa 23rd of April 2018 ...

Thus Agema agrees this price is cheap and Scancell is a buy at this level.
Mon 09:48

Happy birthday ..
Sun 10:07

anyway your just waffling ...

so leave you with it
Sun 10:06

what ???

this are your words .... not mine

"""However it is often these shares which rise and fall most quickly.It is Market Cap which is a better indicator of progress rather than SP unless you are a trader."""

i guess you have just researched MCAP ...
Sun 09:57

Nobody is buying and selling on Points of view,

the problem with generalisation when you don't have a "poll" or a vote, it becomes your personal assumption which is always biased to how you think .. and then your trying to think for others ...

every one is a individual as such buy sell or hold is personal, and that applies to risk and reward also ...

what bugs me is when so called experts generalise Scancell ... well other shares did that so Scancell might ....

that sort of statement is a bad reflection of the writers inability to quantify Scancell ... so has to Generalise

Big Pharma have pipelines in development ...... or have you not understood my posts ... ?
Sun 09:48

Ivy

"""However it is often these shares which rise and fall most quickly.It is Market Cap which is a better indicator of progress rather than SP unless you are a trader."""

explain what market Cap is ... ?

and does it change with the SP


Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days
Lakshmi8882,877
Wassatt1,576
Alfacomp1,293
CHELSEA71,287
kenny1001,274
Troajan1,140
MisterPositive1,035
robbo99953





Member Login

Forgotten your password?
Email:

Password:


Don't have an account? Click here to Register Free!




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.